Study Shows Secondary Surgery Does Not Improve Overall Survival for Recurrent Ovarian Cancer Patients: University of Texas
November 14, 2019
November 14, 2019
HOUSTON, Texas, Nov. 14 [TNSmedicalresearch-New England Journal of Medicine] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.
The Phase III Gynecologic On . . .
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.
The Phase III Gynecologic On . . .